Achieving the ROI in Personalized Medicine: Barriers, Incentives and Pathways to Successful CommercializationWatch the video sessions of the Personalized Medicine Conference |
The Deloitte Center for Health Solutions, which is a part of Deloitte LLP, recently released a report titled "The ROI for Targeted Therapies: A Strategic Perspective" at a Personalized Medicine Coalition conference, "Achieving ROI in Personalized Medicine: Barriers, Incentives, and Pathways to Successful Commercialization." This conference offered participants a first look at the findings of the Deloitte study that investigated the return on investment (ROI) in personalized medicine for four key stakeholder groups: consumers, payors, biotechnology/pharmaceutical companies, and diagnostic companies.
This event brought together leaders in business and policy to address questions about the pathway to achieving the potential of personalized medicine. In the morning session, Paul Keckley (PhD), Executive Director of Deloitte Center for Health Solutions, provided a keynote address of the findings of the study, followed by a moderated discussion with industry executives from the pharmaceutical, diagnostic, and health plan sector about the implications of the findings. In the afternoon, the sessions turned their focus towards the policy issues and barriers faced while adopting personalized medicine.
Watch the series of videos by clicking on the screen below:
The videos in this series include:
Recap of the conference highlights (10-minutes)
Setting the Stage: ROI in Personalized Medicine: Pathways and Barriers
Paul Keckley, PhD, Executive Director, Deloitte Center for Health Solutions
Panel Perspectives and Q&A session
Moderator: Paul Keckley, PhD, Executive Director, Deloitte Center for Health Solutions
Speakers:
Aidan C. Power, Vice President & Global Head of Molecular Medicine, Pfizer Global Research and Development
Randy Scott, Chairman and CEO, Genomic Health
James Utley, Vice President and Medical Director of the Commercial Business Division, Coventry Health Care
Bridging the Gap: Healthcare Reform and Its Potential Impact on the Development and Adoption of Personalized Medicine
The Honorable W. J. Billy Tauzin, President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America (PhRMA)
A National Leadership Perspective on Personalized Medicine
Francis Collins, Former Director of National Human Genome Research Institute, National Institutes of Health
The Critical Path Initiative: Breaking Down Barriers at FDA
Janet Woodcock, Director, Center for Drug Evaluation and Research, FDA
Stay Connected:
Subscribe to receive updates from the Deloitte Center for Health Solutions:
E-mail | 
RSS (What is RSS?) | 
Twitter
Last updated
